Regional variation of thigh muscle fat infiltration in patients with neuromuscular diseases compared to healthy controls.
Water-fat magnetic resonance imaging (water-fat MRI)
late-onset Pompe disease (LOPD)
limb-girdle muscular dystrophy type 2A (LGMD2A)
myotonic dystrophy type 2 (DM2)
neuromuscular disease (NMD)
proton density fat fraction (PDFF)
Journal
Quantitative imaging in medicine and surgery
ISSN: 2223-4292
Titre abrégé: Quant Imaging Med Surg
Pays: China
ID NLM: 101577942
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
entrez:
3
6
2021
pubmed:
4
6
2021
medline:
4
6
2021
Statut:
ppublish
Résumé
Chemical shift encoding-based water-fat magnetic resonance imaging (CSE-MRI) measures a quantitative biomarker: the proton density fat fraction (PDFF). The aim was to assess regional and proximo-distal PDFF variations at the thigh in patients with myotonic dystrophy type 2 (DM2), limb-girdle muscular dystrophy type 2A (LGMD2A), and late-onset Pompe disease (LOPD) as compared to healthy controls. Seven patients (n=2 DM2, n=2 LGMD2A, n=3 LOPD) and 20 controls were recruited. A 3D-spoiled gradient echo sequence was used to scan the thigh musculature. Muscles were manually segmented to generate mean muscle PDFF. In all three disease entities, there was an increase in muscle fat replacement compared to healthy controls. However, within each disease group, there were patients with a shorter time since symptom onset that only showed mild PDFF elevation (range, 10% to 20%) compared to controls (P≤0.05), whereas patients with a longer period since symptom onset showed a more severe grade of fat replacement with a range of 50% to 70% (P<0.01). Increased PDFF of around 5% was observed for vastus medialis, semimembranosus and gracilis muscles in advanced compared to early DM2. LGMD2A_1 showed an early disease stage with predominantly mild PDFF elevations over all muscles and levels (10.9%±7.1%) compared to controls. The quadriceps, gracilis and biceps femoris muscles showed the highest difference between LGMD2A_1 with 5 years since symptom onset (average PDFF 11.1%±6.9%) compared to LGMD2A_2 with 32 years since symptom onset (average PDFF 66.3%±6.3%). For LOPD patients, overall PDFF elevations were observed in all major hip flexors and extensors (range, 25.8% to 30.8%) compared to controls (range, 1.7% to 2.3%, P<0.05). Proximal-to-distal PDFF highly varied within and between diseases and within controls. The intra-reader reliability was high (reproducibility coefficient ≤2.19%). By quantitatively measuring muscle fat infiltration at the thigh, we identified candidate muscles for disease monitoring due to their gradual PDFF elevation with longer disease duration. Regional variation between proximal, central, and distal muscle PDFF was high and is important to consider when performing longitudinal MRI follow-ups in the clinical setting or in longitudinal studies.
Sections du résumé
BACKGROUND
BACKGROUND
Chemical shift encoding-based water-fat magnetic resonance imaging (CSE-MRI) measures a quantitative biomarker: the proton density fat fraction (PDFF). The aim was to assess regional and proximo-distal PDFF variations at the thigh in patients with myotonic dystrophy type 2 (DM2), limb-girdle muscular dystrophy type 2A (LGMD2A), and late-onset Pompe disease (LOPD) as compared to healthy controls.
METHODS
METHODS
Seven patients (n=2 DM2, n=2 LGMD2A, n=3 LOPD) and 20 controls were recruited. A 3D-spoiled gradient echo sequence was used to scan the thigh musculature. Muscles were manually segmented to generate mean muscle PDFF.
RESULTS
RESULTS
In all three disease entities, there was an increase in muscle fat replacement compared to healthy controls. However, within each disease group, there were patients with a shorter time since symptom onset that only showed mild PDFF elevation (range, 10% to 20%) compared to controls (P≤0.05), whereas patients with a longer period since symptom onset showed a more severe grade of fat replacement with a range of 50% to 70% (P<0.01). Increased PDFF of around 5% was observed for vastus medialis, semimembranosus and gracilis muscles in advanced compared to early DM2. LGMD2A_1 showed an early disease stage with predominantly mild PDFF elevations over all muscles and levels (10.9%±7.1%) compared to controls. The quadriceps, gracilis and biceps femoris muscles showed the highest difference between LGMD2A_1 with 5 years since symptom onset (average PDFF 11.1%±6.9%) compared to LGMD2A_2 with 32 years since symptom onset (average PDFF 66.3%±6.3%). For LOPD patients, overall PDFF elevations were observed in all major hip flexors and extensors (range, 25.8% to 30.8%) compared to controls (range, 1.7% to 2.3%, P<0.05). Proximal-to-distal PDFF highly varied within and between diseases and within controls. The intra-reader reliability was high (reproducibility coefficient ≤2.19%).
CONCLUSIONS
CONCLUSIONS
By quantitatively measuring muscle fat infiltration at the thigh, we identified candidate muscles for disease monitoring due to their gradual PDFF elevation with longer disease duration. Regional variation between proximal, central, and distal muscle PDFF was high and is important to consider when performing longitudinal MRI follow-ups in the clinical setting or in longitudinal studies.
Identifiants
pubmed: 34079727
doi: 10.21037/qims-20-1098
pii: qims-11-06-2610
pmc: PMC8107331
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2610-2621Informations de copyright
2021 Quantitative Imaging in Medicine and Surgery. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/qims-20-1098). Dr. ML reports grants from the European Research Council, during the conduct of the study. Dr. DCK reports grants from Philips Healthcare, outside the submitted work. Dr. JSK reports grants from German Society for Muscle Diseases, during the conduct of the study. The other authors have no conflicts of interest to declare.
Références
J Magn Reson Imaging. 2015 Oct;42(4):1018-23
pubmed: 25639780
PLoS One. 2016 Sep 20;11(9):e0162542
pubmed: 27649492
J Magn Reson Imaging. 2011 Oct;34(4):928-34
pubmed: 21769986
Neuromuscul Disord. 2004 Jan;14(1):51-5
pubmed: 14659413
Nutrients. 2018 Dec 13;10(12):
pubmed: 30551614
PLoS One. 2013 Sep 09;8(9):e73990
pubmed: 24040139
Eur J Radiol. 2016 Aug;85(8):1512-8
pubmed: 26905521
J Inherit Metab Dis. 2010 Dec;33(6):737-45
pubmed: 20844963
J Comput Assist Tomogr. 2016 May-Jun;40(3):447-51
pubmed: 26953765
Front Endocrinol (Lausanne). 2018 Apr 04;9:141
pubmed: 29670577
Acta Myol. 2017 Sep 01;36(3):151-162
pubmed: 29774305
PLoS One. 2013 Aug 14;8(8):e70993
pubmed: 23967145
Muscle Nerve. 2018 Oct;58(4):550-558
pubmed: 30028523
PLoS One. 2014 Jan 14;9(1):e85416
pubmed: 24454861
J Magn Reson Imaging. 2018 Dec;48(6):1578-1585
pubmed: 29665193
J Inherit Metab Dis. 2015 May;38(3):565-72
pubmed: 25749708
Magn Reson Med. 2007 Aug;58(2):354-64
pubmed: 17654578
Eur J Radiol. 1992 Oct;15(3):230-8
pubmed: 1490449
Skeletal Radiol. 2009 Dec;38(12):1205-8
pubmed: 19771425
Lancet Neurol. 2016 Jan;15(1):65-77
pubmed: 26549782
J Neurol. 2020 Jan;267(1):45-56
pubmed: 31555977
Eur J Radiol. 1993 Nov;17(3):141-4
pubmed: 8293736
J Magn Reson Imaging. 2012 Nov;36(5):1011-4
pubmed: 22777847
J Magn Reson Imaging. 2018 Apr;47(4):995-1002
pubmed: 28851124
PLoS One. 2016 Oct 6;11(10):e0163493
pubmed: 27711114
Neurol Clin. 2014 Aug;32(3):751-76, ix
pubmed: 25037089
PLoS One. 2019 Dec 5;14(12):e0226037
pubmed: 31805136
Muscle Nerve. 2018 Aug;58(2):167-177
pubmed: 29350766
Neuromuscul Disord. 2009 May;19(5):357-62
pubmed: 19329315
Front Endocrinol (Lausanne). 2018 Sep 28;9:563
pubmed: 30323789
Magn Reson Imaging. 2008 Apr;26(3):347-59
pubmed: 18093781
Neuromuscul Disord. 2005 Feb;15(2):164-71
pubmed: 15694138
Radiology. 2010 Jun;255(3):899-908
pubmed: 20501727
Front Endocrinol (Lausanne). 2015 Mar 30;6:40
pubmed: 25870585
Magn Reson Med. 2011 Nov;66(5):1312-26
pubmed: 21452279
J Neurol. 2005 May;252(5):538-47
pubmed: 15726252
Neuromuscul Disord. 2017 May;27(5):458-464
pubmed: 28302391
PLoS One. 2014 Feb 28;9(2):e90377
pubmed: 24587344
Skeletal Radiol. 2012 Aug;41(8):955-61
pubmed: 22069033
Neurology. 2017 Nov 14;89(20):2057-2065
pubmed: 29030457
Ann Neurol. 2016 Apr;79(4):535-47
pubmed: 26891991
J Neurol. 2006 Jun;253(6):753-61
pubmed: 16511650
J Neurol. 2017 Oct;264(10):2053-2067
pubmed: 28669118
MAGMA. 2016 Apr;29(2):245-57
pubmed: 26983429
Eur Radiol. 2019 Feb;29(2):599-608
pubmed: 30014202
J Neurol. 2017 Jul;264(7):1320-1333
pubmed: 27888415